A retrospective analysis of the revocation of prior authorization restrictions and the use of antidepressant medications for treating major depressive disorder

Clinical Therapeutics

Volumn 24, Issue 11, 2002, Pages 1939-1959

  McCombs, Jeffrey S ^a   Shi, Lizheng ^a   Stimmel, Glen L ^a   Croghan, Thomas W ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Compliance; Prior authorization restrictions; SSRIs; Switching

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; DESIPRAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MIRTAZAPINE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PERPHENAZINE; PROTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE;

ADULT; ARTICLE; DOSE RESPONSE; DRUG USE; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PATIENT COMPLIANCE; PHYSICIAN; RETROSPECTIVE STUDY; TREATMENT WITHDRAWAL;

EID: 0036860293     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(02)80090-X     Document Type: Article

References (28)

1. Skaer TL, Sclar DA, Robison LM, et al. Economic valuation of amitriptyline, desipramine, nortriptyline and sertraline in the management of patients with depression. Curr Ther Res Clin Exp. 1995;56:556-567.
2. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: Economic outcomes in a health maintenance organization. Clin Ther. 1994;16:715-730.
3. McCombs JS, Nichol MB, Stimmel GL. The role of SSRI anti-depressants for treating depressed patients in the California Medicaid (Medi-Cal) Program. Value in Health. 1999;2:269-280.
4. Simon GE, VonKorff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA. 1996;275:1897-1902.
5. Simon GE, Heiligenstein J, Revicki D, et al. Long-term outcomes of initial antidepressant drug choice in a "real world" randomized trial. Arch Fam Med. 1999;8:319-325.
6. Agency for Health Care Policy and Research. Depression in Primary Care: Detection, Diagnosis and Treatment. Quick Reference Guide for Clinicians (No. 5). Rockville, Md: Public Health Service, US Department of Health and Human Services; 1993. AHCPR Publication No. 93-0552.
7. International Classification of Diseases, Ninth Revision, Clinical Modification. 4th Ed. Washington, DC: US Department of Health and Human Services; 1991. Publication No. 91-1260.
8. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry. 2000;157(Suppl 4):1-45.
9. Tierney R, Melfi CA, Singa W, Croghan TW. Antidepressant use and use patterns in naturalistic settings. Drug Benefit Trends/Behavioral Health Trends. 2000;12:7BH-12BH.
10. Logistic Regression Examples Using the SAS System. SAS Version 6.10. 1st Ed. Cary, NC: SAS Institute Inc; 1995:81-86.
11. 2 measures based on Wald and likelihood ratio joint significance tests. American Statistician. 1990;44:250-253.
12. Nagelkerke NJ. A note on a general definition of the coefficient of determination. Biometrika. 1991;78:691-692.
13. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
14. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Soc. 1984;79:516-524.
15. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265-2281.
16. Tai-Seale M, Croghan TW, Obenchain RL. Determinants of antidepressant treatment compliance: Implications for policy. Med Care Res Rev. 2000;57:491-512.
17. Heckman JJ. Treatment selection as a specification error. Econometrica. 1979;47:153-161.
18. Lee LF. Generalized econometric models with selectivity. Econometrica. 1983;51:507-512.
19. Sherbourne CD, Schoenbaum M, Wells K, Croghan TW. Characteristics, treatment patterns, and outcomes of depressed patients with persistent major depression. Presented at: 15th Annual National Institute of Mental Health Meeting on Services Research; Washington, DC; April 2, 2002.
20. Rost K, Smith R, Matthews DB, Guise B. The deliberate misdiagnosis of major depression in primary care. Arch Fam Med. 1994;3:333-337.
21. Freeman VG, Rathore SS, Weinfurt KP, et al. Lying for patients: Physician deception of third-party payers. Arch Intern Med. 1999;159:2263-2270.
22. Klinkman MS, Coyne JC, Gallo S, Schwenk TL. False positives, false negatives, and the validity of the diagnosis of major depression in primary care. Arch Fam Med. 1998;7:451-461.
23. Tiemens BG, VonKorff M, Lin EHB. Diagnosis of depression by primary care physicians versus a structured diagnostic interview. Understanding discordance. Gen Hosp Psychiatry. 1999;21:87-96.
24. Dwight-Johnson M, Sherbourne CD, Liao D, Wells KB. Treatment preferences among depressed primary care patients. J Gen Intern Med. 2000;15:527-534.
25. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160:2101-2107.
26. Croghan TW, Tomlin M, Pescosolido BA, et al. Americans' knowledge and attitudes towards and their willingness to use psychiatric medications. J Nerv Ment Dis. In press.
27. Beasley CM Jr, Sayler ME, Cunningham GE, et al. Fluoxetine in tricyclic refractory major depressive disorder. J Affect Disord. 1990;20:193-200.
28. Russel JM, Berndt ER, Miceli R, et al. Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline. Am J Manag Care. 1999;5:597-606.